{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:51:48Z","timestamp":1789480308683,"version":"build-2803163510"},"reference-count":54,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,4,1]]},"abstract":"Importance<\/jats:title>Hodgkin lymphoma (HL) survivors have higher rates of colorectal cancer, which may be associated with subdiaphragmatic radiation therapy and\/or alkylating chemotherapy. Although radiation dose-response associations with breast, lung, stomach, pancreatic, and esophageal cancer after HL have been demonstrated, the association of radiation therapy with colorectal cancer remains unclear.<\/jats:p><\/jats:sec>Objective<\/jats:title>To quantify the rate of colorectal cancer according to radiation dose to the large bowel and procarbazine dose among HL survivors.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>A nested case-control study examined 5-year HL survivors at 5 hospital centers in the Netherlands. Participants had been diagnosed with HL in 1964 to 2000, when they were 15 to 50 years of age, and were followed for a median of approximately 26 years. Survivors of HL who developed colorectal cancer and survivors who were selected as controls were individually matched on sex, age at HL diagnosis, and date of HL diagnosis. Data were analyzed from July 2021 to October 2022.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Mean radiation doses to the large bowel were estimated by reconstructing individual radiation therapy treatments on representative computed tomography data sets.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Excess rate ratios (ERRs) were modeled to evaluate the excess risk associated with each 1-gray increase in radiation dose, and potential effect modification by procarbazine was explored.<\/jats:p><\/jats:sec>Results<\/jats:title>The study population included 316 participants (mean [SD] age at HL diagnosis, 33.0 [9.8] years; 221 [69.9%] men), 78 of whom were HL survivors who developed colorectal cancer (cases) and 238 who did not (controls). The median (IQR) interval between HL and colorectal cancer was 25.7 (18.2-31.6) years. Increased colorectal cancer rates were seen for patients who received subdiaphragmatic radiation therapy (rate ratio [RR], 2.4; 95% CI, 1.4-4.1) and those who received more than 8.4 g\/m2<\/jats:sup> procarbazine (RR, 2.5; 95% CI, 1.3-5.0). Overall, colorectal cancer rate increased linearly with mean radiation dose to the whole large bowel and dose to the affected bowel segment. The association between radiation dose and colorectal cancer rate became stronger with increasing procarbazine dose: the ERR per gray to the whole bowel was 3.5% (95% CI, 0.4%-12.6%) for patients who did not receive procarbazine, and increased 1.2-fold (95% CI, 1.1-1.3) for each 1-g\/m2<\/jats:sup> increase in procarbazine dose.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This nested case-control study of 5-year HL survivors found a dose-response association between radiation therapy and colorectal cancer risk, and modification of this association by procarbazine. These findings may enable individualized colorectal cancer risk estimations, identification of high-risk survivors for subsequent screening, and optimization of treatment strategies.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2022.7153","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T16:09:24Z","timestamp":1675354164000},"page":"481","source":"Crossref","is-referenced-by-count":15,"title":["Association of Radiation and Procarbazine Dose With Risk of Colorectal Cancer Among Survivors of Hodgkin Lymphoma"],"prefix":"10.1001","volume":"9","author":[{"given":"Yvonne M.","family":"Geurts","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, the Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Shakir","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Ntentas","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford, Oxford, UK"},{"name":"Department of Medical Physics, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, UK"},{"name":"School of Biomedical Engineering and Imaging Sciences, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Roberti","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, the Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne C.","family":"Aznar","sequence":"additional","affiliation":[{"name":"Division of Cancer Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katinka M.","family":"John","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, the Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Ramroth","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile P. M.","family":"Janus","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustinus D. G.","family":"Krol","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith M.","family":"Roesink","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W. M.","family":"van der Maazen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9e M.","family":"Zijlstra","sequence":"additional","affiliation":[{"name":"Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit, Cancer Center Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Darby","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthe M. P.","family":"Aleman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora E.","family":"van Leeuwen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, the Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Cutter","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford, Oxford, UK"},{"name":"Oxford Cancer and Hematology Center, Oxford University Hospitals National Health Service Foundation Trust, Churchill Hospital, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schaapveld","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, the Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"coi220093r2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1200\/JCO.1994.12.2.312","article-title":"Second cancer risk following Hodgkin\u2019s disease: a 20-year follow-up study.","volume":"12","author":"van Leeuwen","year":"1994","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi220093r3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0360-3016(96)00489-0","article-title":"Gastrointestinal cancer after treatment of Hodgkin\u2019s disease.","volume":"37","author":"Birdwell","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"coi220093r4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1200\/JCO.2000.18.3.498","article-title":"Risk of second malignancy after Hodgkin\u2019s disease in a collaborative British cohort: the relation to age at treatment.","volume":"18","author":"Swerdlow","year":"2000","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi220093r5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/JCO.2000.18.3.487","article-title":"Long-term risk of second malignancy in survivors of Hodgkin\u2019s disease treated during adolescence or young adulthood.","volume":"18","author":"van Leeuwen","year":"2000","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi220093r6","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1200\/JCO.2000.18.12.2435","article-title":"Second cancers among long-term survivors of Hodgkin\u2019s disease diagnosed in childhood and adolescence.","volume":"18","author":"Metayer","year":"2000","journal-title":"J Clin Oncol"},{"issue":"16","key":"coi220093r7","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1200\/JCO.2002.09.038","article-title":"Second malignant neoplasms among long-term survivors of Hodgkin\u2019s disease: a population-based evaluation over 25 years.","volume":"20","author":"Dores","year":"2002","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi220093r8","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1182\/blood-2002-02-0634","article-title":"Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors.","volume":"100","author":"Ng","year":"2002","journal-title":"Blood"},{"issue":"12","key":"coi220093r9","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1200\/JCO.2006.09.0936","article-title":"Long-term solid cancer risk among 5-year survivors of Hodgkin\u2019s lymphoma.","volume":"25","author":"Hodgson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi220093r10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/bjc.2017.177","article-title":"Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors.","volume":"117","author":"van Eggermond","year":"2017","journal-title":"Br J Cancer"},{"issue":"31","key":"coi220093r11","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1200\/JCO.2011.34.8268","article-title":"Second cancer risk after chemotherapy for Hodgkin\u2019s lymphoma: a collaborative British cohort study.","volume":"29","author":"Swerdlow","year":"2011","journal-title":"J Clin Oncol"},{"issue":"26","key":"coi220093r12","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma.","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"issue":"13","key":"coi220093r13","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/jnci\/95.13.971","article-title":"Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin\u2019s disease.","volume":"95","author":"van Leeuwen","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"coi220093r14","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.ijrobp.2017.07.016","article-title":"Breast cancer risk after radiation therapy for Hodgkin lymphoma: influence of gonadal hormone exposure.","volume":"99","author":"Krul","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"coi220093r15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","article-title":"Lung cancer following chemotherapy and radiotherapy for Hodgkin\u2019s disease.","volume":"94","author":"Travis","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"27","key":"coi220093r16","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1200\/JCO.2013.50.6832","article-title":"Stomach cancer risk after treatment for Hodgkin lymphoma.","volume":"31","author":"Morton","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi220093r17","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/annonc\/mdu287","article-title":"Pancreatic cancer risk after treatment of Hodgkin lymphoma.","volume":"25","author":"Dores","year":"2014","journal-title":"Ann Oncol"},{"issue":"10","key":"coi220093r18","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.3324\/haematol.2014.108258","article-title":"Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma.","volume":"99","author":"Morton","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"coi220093r19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2307\/2530744","article-title":"Biased selection of controls for case-control analyses of cohort studies.","volume":"40","author":"Lubin","year":"1984","journal-title":"Biometrics"},{"issue":"3","key":"coi220093r21","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.1016\/j.ijrobp.2012.01.023","article-title":"Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas.","volume":"83","author":"Gay","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"coi220093r22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.prro.2013.06.004","article-title":"Upper abdominal normal organ contouring guidelines and atlas: a Radiation Therapy Oncology Group consensus.","volume":"4","author":"Jabbour","year":"2014","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"coi220093r23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.23922\/jarc.2019-018","article-title":"Japanese classification of colorectal, appendiceal, and anal carcinoma: the 3rd English edition.","volume":"3","author":"Japanese Society for Cancer of the Colon and Rectum","year":"2019","journal-title":"J Anus Rectum Colon"},{"issue":"32","key":"coi220093r24","first-page":"5","article-title":"Statistical methods in cancer research: volume I, the analysis of case-control studies.","author":"Breslow","year":"1980","journal-title":"IARC Sci Publ"},{"issue":"6","key":"coi220093r25","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/ije\/22.6.1189","article-title":"What does the odds ratio estimate in a case-control study?","volume":"22","author":"Pearce","year":"1993","journal-title":"Int J Epidemiol"},{"issue":"6","key":"coi220093r26","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","article-title":"A new look at the statistical model identification.","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Trans Automat Contr"},{"issue":"26","key":"coi220093r27","doi-asserted-by":"publisher","first-page":"5831","DOI":"10.1002\/sim.v40.26","article-title":"Bias correction for estimates from linear excess relative risk models in small case-control studies.","volume":"40","author":"Roberti","year":"2021","journal-title":"Stat Med"},{"issue":"1","key":"coi220093r29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2307\/3577477","article-title":"Radiation dose and second cancer risk in patients treated for cancer of the cervix.","volume":"116","author":"Boice","year":"1988","journal-title":"Radiat Res"},{"issue":"4","key":"coi220093r30","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1269\/jrr.33.342","article-title":"Colorectal cancer incidence among atomic bomb survivors, 1950-80.","volume":"33","author":"Nakatsuka","year":"1992","journal-title":"J Radiat Res"},{"issue":"2","key":"coi220093r31","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ijrobp.2012.09.001","article-title":"Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship.","volume":"86","author":"Berrington de Gonzalez","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"coi220093r32","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/09553000010022634","article-title":"Comparison of the risks of cancer incidence and mortality following radiation therapy for benign and malignant disease with the cancer risks observed in the Japanese A-bomb survivors.","volume":"77","author":"Little","year":"2001","journal-title":"Int J Radiat Biol"},{"issue":"5","key":"coi220093r35","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.ijrobp.2009.01.073","article-title":"Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy.","volume":"75","author":"van den Belt-Dusebout","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1-2","key":"coi220093r36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1383-5718(98)00002-3","article-title":"Organ-specific genotoxicity of the potent rodent colon carcinogen 1,2-dimethylhydrazine and three hydrazine derivatives: difference between intraperitoneal and oral administration.","volume":"415","author":"Sasaki","year":"1998","journal-title":"Mutat Res"},{"issue":"20","key":"coi220093r37","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1200\/JCO.2011.37.8760","article-title":"Secondary colorectal carcinoma after childhood cancer.","volume":"30","author":"Nottage","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi220093r38","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/cncr.31903","article-title":"High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors.","volume":"125","author":"Rigter","year":"2019","journal-title":"Cancer"},{"issue":"11","key":"coi220093r39","doi-asserted-by":"publisher","first-page":"757","DOI":"10.7326\/0003-4819-156-11-201206050-00002","article-title":"Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study.","volume":"156","author":"Henderson","year":"2012","journal-title":"Ann Intern Med"},{"issue":"1","key":"coi220093r40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.semradonc.2005.08.001","article-title":"Biologic basis for combining drugs with radiation.","volume":"16","author":"Wilson","year":"2006","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"coi220093r41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1053\/srao.2003.50002","article-title":"The mechanism of action of radiosensitization of conventional chemotherapeutic agents.","volume":"13","author":"Lawrence","year":"2003","journal-title":"Semin Radiat Oncol"},{"issue":"14","key":"coi220093r42","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/jnci\/87.14.1067","article-title":"Postmenopausal hormone use and risk of large-bowel cancer.","volume":"87","author":"Newcomb","year":"1995","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"coi220093r43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u2019s Health Initiative randomized controlled trial.","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"10","key":"coi220093r44","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMoa032071","article-title":"Estrogen plus progestin and colorectal cancer in postmenopausal women.","volume":"350","author":"Chlebowski","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"coi220093r45","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00384-012-1628-y","article-title":"Oestrogen and colorectal cancer: mechanisms and controversies.","volume":"28","author":"Foster","year":"2013","journal-title":"Int J Colorectal Dis"},{"issue":"9","key":"coi220093r46","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju207","article-title":"Risk of premature menopause after treatment for Hodgkin\u2019s lymphoma.","volume":"106","author":"Swerdlow","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"coi220093r47","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1182\/blood-2007-05-090225","article-title":"Treatment-related risk factors for premature menopause following Hodgkin lymphoma.","volume":"111","author":"De Bruin","year":"2008","journal-title":"Blood"},{"key":"coi220093r48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.radonc.2020.08.022","article-title":"Dose-response relationships for radiation-related heart disease: Impact of uncertainties in cardiac dose reconstruction.","volume":"153","author":"Ntentas","year":"2020","journal-title":"Radiother Oncol"},{"issue":"4","key":"coi220093r49","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv008","article-title":"Risk of valvular heart disease after treatment for Hodgkin lymphoma.","volume":"107","author":"Cutter","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"coi220093r50","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","article-title":"The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies.","volume":"13","author":"van Leeuwen","year":"2018","journal-title":"Radiat Oncol"},{"issue":"2","key":"coi220093r51","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1667\/RR14453.1","article-title":"Stomach cancer following Hodgkin lymphoma, testicular cancer and cervical cancer: a pooled analysis of three international studies with a focus on radiation effects.","volume":"187","author":"Gilbert","year":"2017","journal-title":"Radiat Res"},{"issue":"4","key":"coi220093r52","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jama.290.4.465","article-title":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease.","volume":"290","author":"Travis","year":"2003","journal-title":"JAMA"},{"issue":"1","key":"coi220093r53","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/jcm9010190","article-title":"Diagnostic accuracy of stool tests for colorectal cancer surveillance in Hodgkin lymphoma survivors.","volume":"9","author":"Ykema","year":"2020","journal-title":"J Clin Med"},{"issue":"12","key":"coi220093r54","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1158\/1055-9965.EPI-22-0019","article-title":"Cost-effectiveness of colorectal cancer surveillance in Hodgkin lymphoma survivors treated with procarbazine and\/or infradiaphragmatic radiotherapy.","volume":"31","author":"Ykema","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"coi220093r28","volume-title":"Epicure: user\u2019s guide","author":"Preston","year":"1993"},{"key":"coi220093r34","volume-title":"Holland-Frei Cancer Medicine","author":"Colvin","year":"2003","edition":"6th ed"},{"key":"coi220093r1","unstructured":"Netherlands Cancer Registry. IKNL. Accessed February 15, 2022. https:\/\/iknl.nl\/nkr-cijfers"},{"key":"coi220093r20","unstructured":"World Health Organization. International Classification of Diseases for Oncology (ICD-O). 3rd edition, 1st revision. Accessed December 20, 2022. https:\/\/apps.who.int\/iris\/handle\/10665\/96612"},{"key":"coi220093r33","unstructured":"International Agency for Research on Cancer Working Group on the Evaluation of Carcinogenic Risks to Humans. Procarbazine hydrochloride (group 2A). In: Overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1 to 42. 1987. Accessed December 20, 2022. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK533487\/"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2800988\/jamaoncology_geurts_2023_oi_220093_1681755670.06281.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T16:43:13Z","timestamp":1682008993000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2800988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2022.7153","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,1]]}}}